Advanced Tactile Imaging, Inc.

We are driven to provide new and innovative ways of diagnosing and treating health conditions that affect women everywhere. We are simultaneously developing two cutting-edge diagnostic platforms by collaborating with world-renowned physicians and researchers. We believe that an objective understanding of facts is crucial to develop the best technologies. We believe that thoughts must be openly considered and scrutinized to advance our ability to bring technology that is clinically useful to the market which can improve patient outcomes. We believe that we must strive to follow the best ideas and remain agnostic to the stage of development. We believe that the only way to ensure rigorous scientific inquiry is with a strong foundation of support and respect. Our pipeline consists of technologies developed by leading researchers in their fields. Preterm birth is a major global health problem.

Our products have been deployed in more than 8 countries to date on more than 1000 patients. Our vision is to sustainably improve access to women’s cancer prevention with a low-cost, hand-held, portable imaging devices, mHealth communication platforms, and an automated decision-making algorithm. Our vision is to sustainably improve access to women’s cancer prevention with a low-cost, hand-held, portable imaging devices. Not only did these diverse group of partners help to inform product development through the human centered design process, but these very stakeholders have demonstrated that our robust technologies can be used in a wide variety of settings and by gynecologists, obstetricians, nurses, midwives and medical officers. Our latest product launch, The Pocket Colposcope, received FDA clearance in September 2018. Opt-in to receive the latest updates on Calla Health Technology products, research, and innovations. Calla Health is a newly formed entity dedicated to improving the lives of women through technological innovations. The key innovation that will help us achieve our goal is a product called the Pocket Colposcope, which was created as a result of a 3-year human centered design process between Duke , 3rd Stone Design and clinical partners in the U.S., Peru, Tanzania, Zambia and Kenya.

We are excited to move forward as a leader in cervical cancer diagnostics, evolving into a global leader in the world of FemTech. The Eva Pro mini colposcope provides a superior image quality combining with an advanced software capability, powered by AI and tele health. The ThermoGlide offers immediate point-of-care treatment with minimal discomfort and downtime.

The Company utilized this technology as the baseline and further developed innovative image processing algorithms for enhancing subtle lesions in digital mammograms as its first product and enhancing abnormalities in general radiology images. AIE aims to provide physicians with every possible advantage in the screening and diagnosis of breast cancer and other anatomical diseases. Initial product launch in QTR4 2009 with Hologic.

A NEW ERA OF TISSUE MARKING IS LEADING. A company specializing in innovative solutions in medical technology and patient care. News about the product, production, launch and our team.

Materna Medical is a novel OBGYN platform company, defining a $6B market in the most common pelvic conditions women face. Our first product, Milli, is a vaginal and pelvic floor dilator with adjustable, incremental sizing for women who are trying to achieve intimate health. Our second product, Materna Prep, is currently in clinical trials to see if we can help first-time moms achieve less pelvic muscle injuries and a shorter length of delivery during childbirth. The Milli Vaginal Dilator Milli is the first and only all-in-one expanding dilator used to gradually expand the vagina one millimeter at a time, without the discomfort and inconvenience of having to remove and reinsert differently-sized devices—helping address the vaginal tightness associated with vaginismus. Materna’s second product, Materna Prep, is a clinical-stage OBGYN device aiming to reduce pelvic floor injuries during childbirth. Women who vaginally deliver are 9X more likely to have prolapse and incontinence.